Premium
Minimal Interaction between Gatifloxacin and Oxycodone
Author(s) -
Grant Edward M.,
Nicolau David P.,
Nightingale Charles,
Quintiliani Richard
Publication year - 2002
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/009127002401102759
Subject(s) - gatifloxacin , oxycodone , medicine , bioavailability , trovafloxacin , cmax , pharmacology , pharmacokinetics , crossover study , ciprofloxacin , anesthesia , chemistry , placebo , opioid , antibiotics , biochemistry , receptor , alternative medicine , pathology
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate, such as morphine. This decrease in absorption results in a 36% and 50% lower AUC for trovafloxacin and ciprofloxacin, respectively, which could cause clinical failures. The authors investigated the possibility of a similar interaction between oxycodone and gatifloxacin. Twelve healthy volunteers were randomized in an open‐label, two‐way crossover study to receive oxycodone (5 mg po Q4H) and gatifloxacin (400 mgpo 1 h) after starting the oxycodone or gatifloxacin 4UU mg po alone. Blood samples were drawn at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdosing. No significant difference was noted (p > 0.05) in AUC (31.6 +− 7.3 vs. 31.7 +− 7.1) and C max (3.2 +− 0.6 vs. 3.0 +− 0.6) for gatifloxacin versus gatifloxacin/oxycodone regimens; however, the t max (1.8 +− 0.8 vs. 4.3 +− 1.5) was significantly delayed (p < 0.001). It was concluded that oral oxycodone and gatifloxacin can be administered concomitantly without a significant decrease in bioavailability.